Tamara C. Borsboom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tamara C. Borsboom has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Coen A. C. Ottenheijm
Department of Physiology Amsterdam UMC Amsterdam The Netherlands
2 shared publications - Charlotte Gineste
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS UMR 7104, INSERM UMRS 1258, Université de Strasbourg, 67404 Illkirch, France
1 shared publication - Darren T. Hwee
Research and Early Development, Cytokinetics Inc., South San Francisco, CA 94080, USA
1 shared publication - Fady I. Malik
Cytokinetics, Incorporated, South San Francisco, CA, USA
1 shared publication - Johanna Josepha Maria Takkenberg
Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands
1 shared publication - Jolien W. Roos-Hesselink
Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus MC, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (4)
Sex-Related Differences in Histopathology and Hormonal Associations in Ascending Aortic Aneurysms
Background and Aims: Sex-related differences in ascending aorta aneurysm (AscAA) pathology and the underlying mechanisms remain incompletely understood. In this study, sex-specific patterns of aortic media degeneration (MD) in idiopathic AscAA were investigated. Methods: Aortic tissue and blood samples were obtained from 32 patients undergoing elective AscAA resection (mean age 65.6 years, 25% women). Two donor aortas served as healthy controls. Tissues were evaluated using a modified consensus scoring system assessing elastin integrity, mucoid extracellular matrix accumulation (MEMA), smooth muscle cell organization, and collagen remodeling. Immunohistochemistry was used to quantify extracellular matrix and remodeling markers. Outcome parameters included aortic diameter, immunohistochemical profiling, MD scores, and sex hormone profiling. Results: Absolute ascending aortic diameters did not differ between sexes. Women exhibited significantly more advanced and diffuse MD across all sampled locations, with higher total MD scores before and after adjustment for aortic size. This was attributed to increased elastin degradation, MEMA, and elevated local MMP2 expression, consistent with a degradative remodeling profile. In contrast, men displayed a more focal and inflammatory phenotype, characterized by increased MMP9, cKIT, and CD68 expression, and relatively thicker media. Circulating hormone levels were reduced in both sexes but were not directly associated with MD severity. However, female-specific decreases in DHEA and male-specific decreases in testosterone, AMH, and androstenedione were observed. Conclusions: This study reveals pronounced sex-specific differences in AscAA wall degeneration. Women demonstrate a structurally more vulnerable aortic wall at comparable dilatation, fueling discussion for revision of female treatment plans.
- 26 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (4)
Open AccessSex-Related Differences in Histopathology and Hormonal Associations in Ascending Aortic Aneurysms
Background and Aims: Sex-related differences in ascending aorta aneurysm (AscAA) pathology and the underlying mechanisms remain incompletely understood. In this study, sex-specific patterns of aortic media degeneration (MD) in idiopathic AscAA were investigated. Methods: Aortic tissue and blood samples were obtained from 32 patients undergoing elective AscAA resection (mean age 65.6 years, 25% women). Two donor aortas served as healthy controls. Tissues were evaluated using a modified consensus scoring system assessing elastin integrity, mucoid extracellular matrix accumulation (MEMA), smooth muscle cell organization, and collagen remodeling. Immunohistochemistry was used to quantify extracellular matrix and remodeling markers. Outcome parameters included aortic diameter, immunohistochemical profiling, MD scores, and sex hormone profiling. Results: Absolute ascending aortic diameters did not differ between sexes. Women exhibited significantly more advanced and diffuse MD across all sampled locations, with higher total MD scores before and after adjustment for aortic size. This was attributed to increased elastin degradation, MEMA, and elevated local MMP2 expression, consistent with a degradative remodeling profile. In contrast, men displayed a more focal and inflammatory phenotype, characterized by increased MMP9, cKIT, and CD68 expression, and relatively thicker media. Circulating hormone levels were reduced in both sexes but were not directly associated with MD severity. However, female-specific decreases in DHEA and male-specific decreases in testosterone, AMH, and androstenedione were observed. Conclusions: This study reveals pronounced sex-specific differences in AscAA wall degeneration. Women demonstrate a structurally more vulnerable aortic wall at comparable dilatation, fueling discussion for revision of female treatment plans.
- Open Access
- 20 February 2024
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 156 (4)
Tirasemtiv enhances submaximal muscle tension in an Acta1:p.Asp286Gly mouse model of nemaline myopathy
Nemaline myopathies are the most common form of congenital myopathies. Variants in ACTA1 (NEM3) comprise 15–25% of all nemaline myopathy cases. Patients harboring variants in ACTA1 present with a heterogeneous disease course characterized by stable or progressive muscle weakness and, in severe cases, respiratory failure and death. To date, no specific treatments are available. Since NEM3 is an actin-based thin filament disease, we tested the ability of tirasemtiv, a fast skeletal muscle troponin activator, to improve skeletal muscle function in a mouse model of NEM3, harboring the patient-based p.Asp286Gly variant in Acta1. Acute and long-term tirasemtiv treatment significantly increased muscle contractile capacity at submaximal stimulation frequencies in both fast-twitch extensor digitorum longus and gastrocnemius muscle, and intermediate-twitch diaphragm muscle in vitro and in vivo. Additionally, long-term tirasemtiv treatment in NEM3 mice resulted in a decreased respiratory rate with preserved minute volume, suggesting more efficient respiration. Altogether, our data support the therapeutic potential of fast skeletal muscle troponin activators in alleviating skeletal muscle weakness in a mouse model of NEM3 caused by the Acta1:p.Asp286Gly variant.
- 20 February 2024
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 156 (4)
Open AccessTirasemtiv enhances submaximal muscle tension in an Acta1:p.Asp286Gly mouse model of nemaline myopathy
Nemaline myopathies are the most common form of congenital myopathies. Variants in ACTA1 (NEM3) comprise 15–25% of all nemaline myopathy cases. Patients harboring variants in ACTA1 present with a heterogeneous disease course characterized by stable or progressive muscle weakness and, in severe cases, respiratory failure and death. To date, no specific treatments are available. Since NEM3 is an actin-based thin filament disease, we tested the ability of tirasemtiv, a fast skeletal muscle troponin activator, to improve skeletal muscle function in a mouse model of NEM3, harboring the patient-based p.Asp286Gly variant in Acta1. Acute and long-term tirasemtiv treatment significantly increased muscle contractile capacity at submaximal stimulation frequencies in both fast-twitch extensor digitorum longus and gastrocnemius muscle, and intermediate-twitch diaphragm muscle in vitro and in vivo. Additionally, long-term tirasemtiv treatment in NEM3 mice resulted in a decreased respiratory rate with preserved minute volume, suggesting more efficient respiration. Altogether, our data support the therapeutic potential of fast skeletal muscle troponin activators in alleviating skeletal muscle weakness in a mouse model of NEM3 caused by the Acta1:p.Asp286Gly variant.
- Open Access
- 25 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (17) , 9187
Troponin Variants in Congenital Myopathies: How They Affect Skeletal Muscle Mechanics
The troponin complex is a key regulator of muscle contraction. Multiple variants in skeletal troponin encoding genes result in congenital myopathies. TNNC2 has been implicated in a novel congenital myopathy, TNNI2 and TNNT3 in distal arthrogryposis (DA), and TNNT1 and TNNT3 in nemaline myopathy (NEM). Variants in skeletal troponin encoding genes compromise sarcomere function, e.g., by altering the Ca2+ sensitivity of force or by inducing atrophy. Several potential therapeutic strategies are available to counter the effects of variants, such as troponin activators, introduction of wild-type protein through AAV gene therapy, and myosin modulation to improve muscle contraction. The mechanisms underlying the pathophysiological effects of the variants in skeletal troponin encoding genes are incompletely understood. Furthermore, limited knowledge is available on the structure of skeletal troponin. This review focusses on the physiology of slow and fast skeletal troponin and the pathophysiology of reported variants in skeletal troponin encoding genes. A better understanding of the pathophysiological effects of these variants, together with enhanced knowledge regarding the structure of slow and fast skeletal troponin, will direct the development of treatment strategies.
- 25 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (17) , 9187
Open AccessTroponin Variants in Congenital Myopathies: How They Affect Skeletal Muscle Mechanics
The troponin complex is a key regulator of muscle contraction. Multiple variants in skeletal troponin encoding genes result in congenital myopathies. TNNC2 has been implicated in a novel congenital myopathy, TNNI2 and TNNT3 in distal arthrogryposis (DA), and TNNT1 and TNNT3 in nemaline myopathy (NEM). Variants in skeletal troponin encoding genes compromise sarcomere function, e.g., by altering the Ca2+ sensitivity of force or by inducing atrophy. Several potential therapeutic strategies are available to counter the effects of variants, such as troponin activators, introduction of wild-type protein through AAV gene therapy, and myosin modulation to improve muscle contraction. The mechanisms underlying the pathophysiological effects of the variants in skeletal troponin encoding genes are incompletely understood. Furthermore, limited knowledge is available on the structure of skeletal troponin. This review focusses on the physiology of slow and fast skeletal troponin and the pathophysiology of reported variants in skeletal troponin encoding genes. A better understanding of the pathophysiological effects of these variants, together with enhanced knowledge regarding the structure of slow and fast skeletal troponin, will direct the development of treatment strategies.